AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02910518
Drug: Glucose
RxNorm normalized name: Glucose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: solution~Route of administration: intravenous
Trial: NCT02243631
Drug: Probenecid
RxNorm normalized name: Probenecid
DrugBank: Probenecid (DB01032)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment
Trial: NCT00794625
Drug: Valproate
RxNorm normalized name: Valproate
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard therapeutic doses of valproate, set according to valproic acid blood level, for 8 weeks
Trial: NCT00794625
Drug: Risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Standard therapeutic doses of risperidone for 8 weeks
Trial: NCT02274155
Drug: Anti-OX40 antibody administration
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-OX40 antibody administration at 0.4 mg/kg IV x 3 doses given on Days 1, 3 or 4, and 5 or 6 of study
Trial: NCT02593539
Drug: Nemiralisib
RxNorm normalized name: Nemiralisib
DrugBank: Nemiralisib (DB16253)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be administered nemiralisib
Trial: NCT00259376
Drug: Dronedarone (SR33589)
DrugBank: Dronedarone (DB04855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT00766896
Drug: Aspirin (platelet sensitive versus platelet hyperreactivity)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The dose of aspirin to be prescribed in this study will be 300 mg orally or by nasogastric tube once a day (assisted therapy), with first dose tomography soon after admission if the patient has no indication of thrombolytic therapy. After the acute phase, patients will receive aspirin at a dose of 200 mg/day. Aspirin will be administered in a simple preparation (no buffer, no extended release).
Trial: NCT00151632
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In arm 1: Tacrolimus is administered at half recommended dose: 0,040 mg/Kg x 2 , in order to maintain plasma levels between 6 and 10 ng/ml for the 6 first weeks, between 5 and 8 ng/ml from week 7 to M6 and between 4 and 6 ng/ml between M6 and M12.~In arm 2: Tacrolimus is administered at the recommended dose: 0,075 mg/Kg x 2 , in order to maintain plasma levels between 12 and 20 ng/ml for the 6 first weeks, between 10 and 15 ng/ml from week 7 to week 12, between 8 and 12 ng/ml between M4 and M6 and between 6 and 10 ng/ml between M6 and M12.
Trial: NCT01542541
Drug: Rifaximin
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 550mg BID for 2 days
Trial: NCT02248961
Drug: Fimasartan
RxNorm normalized name: Fimasartan
DrugBank: Fimasartan (DB09279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting dose of Kanarb (Fimasartan) is 60 mg, orally, once a day in the morning. The subjects will visit the clinical site every 4 weeks to measure Arterial blood pressure (ABP). The dose will be doubled in case if SBP ≥140 mmHg or DBP ≥90 mmHg at Visit 3 (Day 28) or at Visit 4 (Day 56).~If necessary, the dose of the study drug may be increased based on the assessment of patient's condition performed at the phone contact (Day14±3). Patient may be called for an unscheduled visit for treatment adjustment (decided individually, with possibility of dose titration as per investigator's judgment, indicated in source documents).~When possibilities are, the patient should be administrated by the study medication at the same time in the morning.
Trial: NCT02248961
Drug: Losartan
RxNorm normalized name: Losartan
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cozaar® (Losartan), manufactured by MERCK SHARP \& DOHME B.V., Netherlands, tablets 50/100 mg
Trial: NCT04048070
Drug: Flurbiprofen Axetil
RxNorm normalized name: Flurbiprofen axetil
DrugBank: Flurbiprofen axetil (DB14938)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One kind of NSAIDs, 200mg for 48 hours after surgery.
Trial: NCT01459887
Drug: CHOP combined with CMAB304
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients treated with CHOP-304 undergo 1 cycle every 3 weeks, received CMAB304 at a dose of 375 mg/m2 on day 1 and CHOP on day 2 of each of the 6 cycles.
Trial: NCT01947699
Drug: Glyburide
RxNorm normalized name: Glyburide
DrugBank: Glyburide (DB01016)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00271206
Drug: Progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: compared to placebo
Trial: NCT00271206
Drug: sugar pill
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compared to progesterone
Trial: NCT01460225
Drug: lubiprostone
RxNorm normalized name: Lubiprostone
DrugBank: Lubiprostone (DB01046)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 24 micrograms twice daily for 1 week
Trial: NCT01213524
Drug: 42 mg transdermal nicotine replacement
RxNorm normalized name: Nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 21-mg nicotine patches
Trial: NCT01213524
Drug: Placebo transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 placebo patches matched to 21-mg nicotine patches
Trial: NCT03568643
Drug: Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Children enrolled in the trial and randomized to azithromycin will receive a 7-day course of oral amoxcillin given in twice-daily doses of 50-100 mg/kg, per the Burkina Faso guidelines for the management of severe acute malnutrition. The first dose will be administered at the time of enrollment and the remaining dose will be administered by the caregiver at home. Enrolled children will also receive RUTF.
Trial: NCT02626455
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab is administered as an infusion at a dose of 375 mg/m2 body surface on Day 1 of each 28-day cycle for patients assigned to R-B and on Day 2 of each 21-day cycle for patients assigned to R-CHOP.
Trial: NCT02626455
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vincristine is administered as an infusion at a dose of 1.4 mg/m2 body surface (maximum dose 2.0 mg) on Day 2 of each 21-day cycle for patients assigned to R-CHOP
Trial: NCT02626455
Drug: Bendamustine
RxNorm normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bendamustine is administered as an infusion at a dose of 90 mg/m2 body surface on Day 1 and Day 2 for patients assigned to R-B
Trial: NCT02626455
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone is given as 100 mg tablets daily from Day 2 to Day 6 for patients assigned to R-CHOP
Trial: NCT02240589
Drug: Memantine
RxNorm normalized name: Memantine
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Day 1 to 3: 10 mg bid memantine. Day 3 to 21: 20 mg bid memantine. Day 21 to 168: 10 mg bid memantine.
Trial: NCT04020003
Drug: Levosimendan
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General treatment group: control the infection, remove or control the original disease, mechanical ventilation, small tidal volume, high PEEP mechanical ventilation strategy, strictly control the capacity, strengthen the airway management, timely nutrition support and intensive rehabilitation treatment. Levosimendan group: on the basis of routine group treatment, 12.5 mg of levosimendan 5% GS 50ml was given on the same day, and the micro-pump was continuously pumped for 24 hours. The initial dose was 0.5 ml/ h, and if the blood pressure was not significantly decreased, the blood pressure was gradually increased to 2.4 ml/ h at the maximum dose, until the pump was over. The above treatment is repeated every 7 days until the offline success or the patient leaves the ICU.
Trial: NCT03146481
Drug: Aceclofenac
RxNorm normalized name: Aceclofenac
DrugBank: Aceclofenac (DB06736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aceclofenac 100 mg tablet given one hour before starting the root canal treatment
Trial: NCT00405119
Drug: AH23844 (lavoltidine)
RxNorm normalized name: Lavoltidine
DrugBank: Lavoltidine (DB12884)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00405119
Drug: NEXIUM (esomeprazole)
RxNorm normalized name: Nexium
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00405119
Drug: ZANTAC (ranitidine)
RxNorm normalized name: ranitidine Injection [Zantac]
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03847649
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1500 mg IV, 60 min, Day 1 every 4 weeks
Trial: NCT03847649
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5mg/kg; PO, Daily cycles 1 \& 2
Trial: NCT03847649
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10mg, PO, Daily cycles 1 \& 2
Trial: NCT03847649
Drug: Tremelimumab
RxNorm normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients previously enrolled on a completed CCTG trial to continue treatment with durvalumab (+/- tremelimumab)
Trial: NCT00023998
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00023998
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00023998
Drug: ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01499563
Drug: ITI-007
RxNorm normalized name: Arthur Itis
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsules containing ITI-007 for 28 days
Trial: NCT01499563
Drug: Risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Capsules containing risperidone for 28 days
Trial: NCT01825798
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin will be dispensed in a liquid suspension of 100 mg/mL. For children 6-9 years of age, metformin will be started at 250 mg at their evening meal for 1 week, followed by the addition of a 250 mg dose at breakfast for 1 week. At the Week 2 visit, if metformin is well-tolerated, the dose will be increased to 500 mg twice daily. For children from 10-17 years of age, metformin will be started at 250 mg at their evening meal for 1 week, followed by the addition of a 250 mg dose at breakfast for 1 week. At the Week 2 visit, if metformin is well-tolerated, the dose will be increased to 500 mg twice daily. At the Week 4 visit, if metformin is well-tolerated, the dose will be increased to 850 mg twice daily.
Trial: NCT00167986
Drug: vancomycin-resistant enterococci and ESBL
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00482157
Drug: Vitamin D (Calcitriol)
RxNorm normalized name: Calcitriol
DrugBank: Vitamin D (DB11094)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00631553
Drug: perflutren lipid microspheres
RxNorm normalized name: perflutren lipid microspheres
DrugBank: Perflutren (DB00556)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.3 ml in 30 ml of saline, infused into vein at 2ml / min and titrated for optimal image quality (not to exceed 10 ml/ min at any time).
Trial: NCT04297332
Drug: Nicotine Replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Receive nicotine patches, gum, or lozenges
Trial: NCT01183390
Drug: Anastrozole
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 mg Tablets
Trial: NCT01490892
Drug: 3D HI and SHI of UCA
RxNorm normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perflutren injection, suspension (IV)0.25 ml followed by 3D Harmonic imaging (HI) then (IV) 20 micro-l/kg followed by 3D subharmonic imaging (SHI)
Trial: NCT00078377
Drug: Armodafinil
RxNorm normalized name: Armodafinil
DrugBank: Armodafinil (DB06413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Armodafinil 250 mg once daily in the morning
Trial: NCT00078377
Drug: Armodafinil
RxNorm normalized name: Armodafinil
DrugBank: Armodafinil (DB06413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Armodafinil 150 mg once daily in the morning
Trial: NCT03554408
Drug: 10-1074-LS
RxNorm normalized name: sulfacetamide
DrugBank: Sulfacetamide (DB00634)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of 10-1074-LS
Trial: NCT03554408
Drug: 10-1074-LS
RxNorm normalized name: sulfacetamide
DrugBank: Sulfacetamide (DB00634)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 10-1074-LS
Trial: NCT01870791
Drug: Omegaven
RxNorm normalized name: Omegaven
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly omegaven infusion in combination with EOX chemotherapy
Trial: NCT02032173
Drug: Ranibizumab 0.5mg
RxNorm normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal injection with standard dose of 0.5 mg/0.05mL Pro re nata (PRN)
Trial: NCT02762383
Drug: Peginterferon Alfa-2
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peginterferon alfa-2a will be administered as 90 micrograms (mcg) via subcutaneous (SC) injection once weekly.
Trial: NCT03712540
Drug: BMS-986278
RxNorm normalized name: BMS-986278
DrugBank: BMS-986278 (DB18011)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration 30 mg
Trial: NCT03712540
Drug: Rifampin
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration 600 mg
Trial: NCT00132678
Drug: Risperdal Consta
RxNorm normalized name: RisperDAL Consta
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 12.5, 25, 37.5 or 50mg intramuscular (IM) injection every 2 weeks
Trial: NCT03620903
Drug: Ibrutinib / Bortezomib / Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Induction (Rituximab / Bortezomib / Ibrutinib), Maintenance I (Ibrutinib / Rituximab), Maintenance II (Ibrutinib)
Trial: NCT03376841
Drug: Cenicriviroc
RxNorm normalized name: Cenicriviroc
DrugBank: Cenicriviroc (DB11758)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet; single-dose oral administration
Trial: NCT01132638
Drug: Magnesium Pantoprazole
DrugBank: Pantoprazole (DB00213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 capsule daily, 40 mg, orally, 30 minutes before breakfast
Trial: NCT01132638
Drug: Magnesium Esomeprazole
RxNorm normalized name: Esomeprazole Magnesium
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 capsule daily, 40 mg, orally, 30 minutes before breakfast
Trial: NCT00719602
Drug: Lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Taken orally twice daily
Trial: NCT00719602
Drug: Lopinavir/Ritonavir
RxNorm normalized name: LOPINAVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Taken orally twice daily
Trial: NCT00719602
Drug: Nevirapine
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Taken orally twice daily
Trial: NCT00719602
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Taken orally twice daily
Trial: NCT01073839
Drug: Cisplatin and Gemcitabine
RxNorm normalized name: Cisplatin
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cisplatin 25 mg/m2 days 1 and 8; next cycle starting day 22. Gemcitabine 1000 mg/m2 days 1 and 8; next cycle starting day 22. Total of 8 cycles.
Trial: NCT02137538
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02137538
Drug: Anastrozole
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01473277
Drug: BT-A (Dysport 500U), Triamcinolone acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients will be randomize to receive an intra-articular injection of BT-A (Dysport 500U) or triamcinolone acetonide (40 mg). Both drugs will be reconstituted with 2.0 ml of saline. Both drugs will be injected in the glenohumeral joint with a standard posterior approach. The time of the intra-articular injection od BT-A or steroid will be considered the time zero for each patient. The primary and secondary efficacy variables will be evaluated in all patients at 1 week, 2 weeks, 4 weeks, 3 months and 6 months after the treatment.
Trial: NCT00004551
Drug: nicotine replacement patch
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01125033
Drug: Vitamin C & Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients in this arm received one tablet of vitamin C (200 mg) and one capsule of vitamin E (400 mg) daily for 8 weeks
Trial: NCT01912222
Drug: IXAZOMIB
RxNorm normalized name: Ixazomib
DrugBank: Ixazomib (DB09570)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01125033
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients in this arm received one tablet of vitamin C (200 mg) and one placebo capsule daily for 8 weeks.
Trial: NCT01125033
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients in this arm received one capsule of vitamin E (400 mg) and one placebo tablet daily for 8 weeks.
Trial: NCT01125033
Drug: Vitamin C Placebo & Vitamin E Placebo
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients in this arm received one placebo capsule and one placebo tablet daily for 8 weeks.
Trial: NCT03258723
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: At 6 months, intervention participants who have not been able to lose weight or bring their HbA1c below the high risk range of 6% (determined by point-of-care testing) will have Metformin prescribed by their provider. Metformin will be prescribed at 500mg twice a day. If no change is seen at 12 months follow up, the dose will be increased to 850mg twice a day.
Trial: NCT00005593
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients receive carboplatin IV continuously over 30 minutes on days 1-5. Patients with residual leukemia in the bone marrow at day 15 may receive a second induction course. Patients who achieve partial or complete remission after 1-2 induction courses receive 1 consolidation course of fludarabine, carboplatin, and topotecan beginning 4-8 weeks after recovery from induction therapy.
Trial: NCT00005593
Drug: fludarabine phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients receive fludarabine IV over 30 minutes on days 1-5. Patients with residual leukemia in the bone marrow at day 15 may receive a second induction course. Patients who achieve partial or complete remission after 1-2 induction courses receive 1 consolidation course of fludarabine, carboplatin, and topotecan beginning 4-8 weeks after recovery from induction therapy.
Trial: NCT00005593
Drug: topotecan hydrochloride
RxNorm normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This is a dose escalation study of topotecan. Patients receive topotecan IV continuously on days 6-8. Patients with residual leukemia in the bone marrow at day 15 may receive a second induction course. Patients who achieve partial or complete remission after 1-2 induction courses receive 1 consolidation course of fludarabine, carboplatin, and topotecan beginning 4-8 weeks after recovery from induction therapy.
Trial: NCT01520389
Drug: MM-151
RxNorm normalized name: manganese sulfate 0.151 MG/ML
DrugBank: Manganese citrate (DB14495)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MM-151
Trial: NCT01520389
Drug: MM-151 + irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MM-151 + irinotecan
Trial: NCT00883103
Drug: 2% Lidocaine jelly
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2% Lidocaine jelly will be applied onto the catheter and then the cotton swab during evaluation of postvoid residual and the Q-tip test.
Trial: NCT00807690
Drug: Tacrolimus ointment
RxNorm normalized name: Tacrolimus Ointment
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus ointment 0.1%every night for at least 3 months, half body side